SLN
Silence Therapeutics plc
NASDAQ · Healthcare · Biotechnology · GB
$14.59
−1.35%Margins
Gross margin
51.0%
EBITDA margin
-9814.0%
EBIT margin
—
Net margin
-9759.2%
FCF margin
-6893.2%
-155.8%
Return on equity
-56.3%
Return on assets
-173.2%
Return on invested capital
0.01x
Asset turnover
-$42.3M
Cash from operations
$1.20
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026